1. Long term outcome in non-multiple sclerosis paediatric acquired demyelinating syndromes.
- Author
-
Wassmer, Evangeline, Billaud, Charly, Absoud, Michael, Abdel-Mannan, Omar, Benetou, Christina, Cummins, Carole, Forrest, Katharine, De Goede, Christian, Eltantawi, Noha, Hickson, Helga, Hussain, Nahin, Jardine, Phil, livingston, John H., Mordekar, Santosh, Ramdas, Sithara, Taylor, Micheal, Vijayakumar, K., West, Siobhan, Whitehouse, William P., and Kneen, Rachel
- Subjects
DEMYELINATION ,PEDIATRIC neurology ,TRANSVERSE myelitis ,MULTIPLE sclerosis ,DISEASE relapse - Abstract
We aimed to study the risks of relapse and long term disability in children with non-MS acquired demyelinating syndromes (ADS). In this prospective, multi-centre study, from the 14 UK pediatric neurology centres, children (<16 years) experiencing a first episode of ADS were recruited from 2010 to 2014. Case report forms were collected prospectively. A total of 269 children were recruited and followed up for a median of 7.2 years. Median age at onset was 9y (IQR 9.5–14.5, 126 females). At last follow-up, 46 (18 %) had MS, 4 AQP4-Ab NMOSD and 206 (80 %) had other ADS, of which 27 (13 %) relapsed. Relapsing MOGAD was the diagnosis in 12/27, 6 were seronegative and 9 did not have antibodies tested. Frequency of relapse differed according to first presentation in non-MS ADS, being least likely in transverse myelitis (p = 0.025). In the non-MS group, MOG-Ab was predictive of relapse (HR = 8.42; p < 0.001) occurring 8 times as often decreasing over time. Long-term difficulties did not differ between children with monophasic vs relapsing diseases. The risk of relapse in non-MS ADS depends on initial diagnosis, and MOG-Ab positivity. Long-term difficulties are observed regardless of relapses and are determined by presenting phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF